缬沙坦胶囊对阿尔茨海默病患者血清脂联素、瘦素水平的影响

Effect of valsartan on the serum adiponectin and leptin levels with Alzheimer disease

目的 探讨脂联素（APN）、瘦素（LEP）在阿尔茨海默病（AD）患者血清中的变化及缬沙坦胶囊治疗AD的可能机制.方法 选取AD患者为研究对象,分为缬沙坦组及对照组,通过认知能力筛查（CASI）-2量表评估AD患者认知损害程度,通过酶联免疫吸附法检测血清APN、LEP的变化.结果 治疗前,缬沙坦组CASI量表评分、血清APN、LEP水平与对照组比,差异无统计学意义（P＞0.05）;治疗后,缬沙坦组患者CASI量表评分较对照组改善（P＜0.05）;血清APN、LEP水平较对照组增高（P＜0.05）.结论 缬沙坦胶囊可以在一定程度上延缓AD的进展,其作用可能通过升高血清APN及LEP的水平来实现.

Objective To explore the changes of serum adiponectin （APN） and leptin （LEP） in patients with Alzheimer disease （AD） and the possible mechanism of valsartan capsule on the treatment of AD. Methods AD patients selected for the study, and were divided into the valsartan group and the control group randomly. Cognitive Ability Screening Scale （CASI） was used to evaluate the degree of cognitive impairment in patients with AD. Enzyme--liked immunosorbent assay （ELISA） was adopted to assay the changes of APN and LEP in serum. Results There was no significant difference about the score of CASI, the expression of serum APN and LEP between the two groups before treatment （P〉 0.05）. After treatment, the score of CASI scale in valsartan group was improved （P 〈 0.05）, the level of serum APN, LEP was higher than the control group （P 〈 0.05）. Conclusions To some extent, valsartan capsule can delay the progress of AD, its effect may be achieved by increasing the levels of serum APN and LEP.